We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
BELLUS Health Inc | NASDAQ:BLU | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 14.74 | 14.74 | 14.75 | 0 | 01:00:00 |
| | | |
Per Share
|
| |
Total
|
| ||||||
|
Public offering price(1)
|
| | |
US$
|
|
| | | |
US$
|
|
| |
|
Underwriting discounts and commissions(2)
|
| | |
US$
|
|
| | | |
US$
|
|
| |
|
Proceeds to BELLUS Health Inc. (before expenses)
|
| | |
US$
|
|
| | | |
US$
|
|
| |
| Jefferies | | |
Evercore ISI
|
| |
RBC Capital Markets
|
|
|
UNDERWRITERS’ POSITION
|
| |
MAXIMUM SIZE
|
| |
EXERCISE PERIOD
|
| |
EXERCISE PRICE
|
|
| Option to purchase additional common shares | | | common shares | | | 30 days after the date of this prospectus supplement | | | US$ per common share | |
|
TABLE OF CONTENTS
|
| | | | | | |
|
PROSPECTUS SUPPLEMENT
|
| | |||||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| CAPITALIZATION | | | |
|
| | |
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| UNDERWRITING | | | |
|
| | |
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| |
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| |
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| |
DOSE
|
| |
PLACEBO-ADJUSTED
CHANGE IN 24-HOUR COUGH FREQUENCY AT DAY 28 |
| |
P-VALUE
|
| ||||||
12.5 mg BID
|
| | |
|
-21.1%
|
| | | |
|
p=0.098
|
| |
50 mg BID
|
| | |
|
-34.4%
|
| | | |
|
p=0.003
|
| |
200 mg BID
|
| | |
|
-34.2%
|
| | | |
|
p=0.005
|
| |
DOSE
|
| |
PLACEBO-ADJUSTED
REDUCTION IN AWAKE COUGH FREQUENCY |
| |
P-VALUE
|
| ||||||
25 mg BID
|
| | |
|
-11%
|
| | | |
|
p=0.14
|
| |
50 mg BID
|
| | |
|
-6%
|
| | | |
|
p=0.46
|
| |
100 mg BID
|
| | |
|
-8%
|
| | | |
|
p=0.41
|
| |
200 mg BID
|
| | |
|
-17%
|
| | | |
|
p=0.09
|
| |
DOSE
|
| |
PLACEBO-ADJUSTED
REDUCTION IN AWAKE COUGH FREQUENCY |
| |
P-VALUE
|
| ||||||
25 mg BID
|
| | |
|
-20%
|
| | | |
|
p=0.0010
|
| |
50 mg BID
|
| | |
|
-18%
|
| | | |
|
p=0.0186
|
| |
100 mg BID
|
| | |
|
-19%
|
| | | |
|
p=0.0320
|
| |
200 mg BID
|
| | |
|
-27%
|
| | | |
|
p=0.0026
|
| |
DOSE
|
| |
PLACEBO-ADJUSTED
REDUCTION IN AWAKE COUGH FREQUENCY |
| |
P-VALUE
|
| ||||||
25 mg BID
|
| | |
|
-28%
|
| | | |
|
p=0.0005
|
| |
50 mg BID
|
| | |
|
-28%
|
| | | |
|
p=0.0003
|
| |
100 mg BID
|
| | |
|
-30%
|
| | | |
|
p=0.0014
|
| |
200 mg BID
|
| | |
|
-32%
|
| | | |
|
p=0.0006
|
| |
PURPOSE
|
| |
ESTIMATED AMOUNT
|
| |||
BLU-5937 clinical trials in chronic cough
|
| | |
US$
|
million
|
| |
Manufacturing, formulation and scale-up
|
| | |
US$
|
million
|
| |
Other project costs, working capital and other general administration
|
| | |
US$
|
million
|
| |
| | |
AS OF MARCH 31, 2022
|
| |||||||||
| | |
ACTUAL
|
| |
AS ADJUSTED
|
| ||||||
| | |
(UNAUDITED)
(IN THOUSANDS OF US$) |
| |||||||||
Cash and cash equivalents
|
| | |
$
|
147,155
|
| | | |
$
|
|
| |
Short-term investments
|
| | |
|
86,813
|
| | | | | | | |
Total
|
| | |
$
|
233,968
|
| | | |
$
|
|
| |
Shareholders’ Equity | | | | | | | | | | | | | |
Share capital (outstanding common shares – 106,744,431; as
adjusted – ) |
| | |
$
|
800,015
|
| | | |
$
|
|
| |
Other equity
|
| | |
|
39,156
|
| | | | | | | |
Deficit
|
| | |
|
(568,676)
|
| | | | | | | |
Accumulated other comprehensive income
|
| | |
|
9,298
|
| | | | | | | |
Total shareholders’ equity
|
| | |
|
279,793
|
| | | | | | | |
Total capitalization
|
| | |
$
|
279,793
|
| | | |
$
|
|
| |
|
DATE OF GRANT
|
| |
NUMBER OF
OPTIONS ISSUED |
| |
EXERCISE PRICE
(PER OPTION) |
|
August 11, 2021
|
| |
20,000
|
| |
US$3.10
|
|
November 10, 2021
|
| |
180,000
|
| |
US$7.04
|
|
February 23, 2022
|
| |
2,945,000
|
| |
US$7.01
|
|
March 23, 2022
|
| |
390,000
|
| |
US$6.38
|
|
May 11, 2022
|
| |
220,000
|
| |
US$7.85
|
|
July 6, 2022
|
| |
200,000
|
| |
US$9.58
|
|
DATE OF ISSUANCE
|
| |
NUMBER OF
SHARES ISSUED |
| |
EXERCISE PRICE
(PER OPTION OR SHARE, AS APPLICABLE) |
|
November 4, 2021
|
| |
888
|
| |
Cdn$1.80
|
|
November 4, 2021
|
| |
7,778
|
| |
Cdn$1.08
|
|
November 8, 2021
|
| |
7,000
|
| |
Cdn$1.80
|
|
December 14, 2021
|
| |
25,000,000
|
| |
US$8.00
|
|
December 23, 2021
|
| |
33,334
|
| |
Cdn$1.08
|
|
December 23, 2021
|
| |
4,000
|
| |
Cdn$3.14
|
|
December 29, 2021
|
| |
3,000,000
|
| |
US$8.00
|
|
January 10, 2022
|
| |
4,111
|
| |
Cdn$1.80
|
|
January 11, 2022
|
| |
3,000
|
| |
Cdn$1.80
|
|
February 17, 2022
|
| |
5,667
|
| |
Cdn$3.78
|
|
March 1, 2022
|
| |
118,520
|
| |
Cdn$1.80
|
|
March 1, 2022
|
| |
86,720
|
| |
Cdn$1.80
|
|
March 3, 2022
|
| |
20,833
|
| |
Cdn$1.80
|
|
March 3, 2022
|
| |
11,111
|
| |
Cdn$1.08
|
|
March 3, 2022
|
| |
16,666
|
| |
Cdn$1.26
|
|
March 22, 2022
|
| |
87,442
|
| |
Cdn$1.80
|
|
April 8, 2022
|
| |
2,072
|
| |
Cdn$3.14
|
|
April 19, 2022
|
| |
1,301
|
| |
Cdn$3.58
|
|
May 20, 2022
|
| |
23,490
|
| |
Cdn$1.26
|
|
| | |
TSX
|
| |
NASDAQ COMPOSITE
|
| ||||||||||||||||||||||||||||||
| | |
HIGH
|
| |
LOW
|
| |
VOLUME
|
| |
HIGH
|
| |
LOW
|
| |
VOLUME
|
| ||||||||||||||||||
| | |
(CDN$)
|
| |
(CDN$)
|
| |
(#)
|
| |
(US$)
|
| |
(US$)
|
| |
(#)
|
| ||||||||||||||||||
July 2021
|
| | |
|
4.00
|
| | | |
|
3.32
|
| | | |
|
689,987
|
| | | |
|
3.22
|
| | | |
|
2.60
|
| | | |
|
10,274,074
|
| |
August 2021
|
| | |
|
4.82
|
| | | |
|
3.54
|
| | | |
|
852,624
|
| | | |
|
3.83
|
| | | |
|
2.82
|
| | | |
|
10,059,420
|
| |
September 2021
|
| | |
|
9.31
|
| | | |
|
4.42
|
| | | |
|
6,012,205
|
| | | |
|
7.35
|
| | | |
|
3.50
|
| | | |
|
115,635,428
|
| |
October 2021
|
| | |
|
9.25
|
| | | |
|
7.10
|
| | | |
|
2,171,242
|
| | | |
|
7.48
|
| | | |
|
5.68
|
| | | |
|
16,812,714
|
| |
November 2021
|
| | |
|
9.47
|
| | | |
|
6.91
|
| | | |
|
1,701,319
|
| | | |
|
7.65
|
| | | |
|
5.41
|
| | | |
|
23,184,217
|
| |
December 2021
|
| | |
|
12.59
|
| | | |
|
6.64
|
| | | |
|
3,968,455
|
| | | |
|
9.84
|
| | | |
|
5.18
|
| | | |
|
153,383,543
|
| |
January 2022
|
| | |
|
10.55
|
| | | |
|
6.30
|
| | | |
|
2,775,604
|
| | | |
|
8.21
|
| | | |
|
4.98
|
| | | |
|
22,294,330
|
| |
February 2022
|
| | |
|
9.40
|
| | | |
|
7.23
|
| | | |
|
2,357,964
|
| | | |
|
7.45
|
| | | |
|
5.61
|
| | | |
|
28,447,599
|
| |
March 2022
|
| | |
|
8.85
|
| | | |
|
7.00
|
| | | |
|
1,601,946
|
| | | |
|
7.11
|
| | | |
|
5.45
|
| | | |
|
10,156,932
|
| |
April 2022
|
| | |
|
11.29
|
| | | |
|
8.46
|
| | | |
|
2,040,624
|
| | | |
|
9.04
|
| | | |
|
6.76
|
| | | |
|
17,818,288
|
| |
May 2022
|
| | |
|
11.68
|
| | | |
|
8.07
|
| | | |
|
3,830,869
|
| | | |
|
9.09
|
| | | |
|
6.35
|
| | | |
|
17,888,269
|
| |
June 2022
|
| | |
|
13.25
|
| | | |
|
9.18
|
| | | |
|
2,040,276
|
| | | |
|
10.28
|
| | | |
|
7.08
|
| | | |
|
19,689,433
|
| |
July 2022 (to July 12)
|
| | |
|
14.46
|
| | | |
|
11.61
|
| | | |
|
1,199,969
|
| | | |
|
11.10
|
| | | |
|
8.82
|
| | | |
|
8,645,989
|
| |
UNDERWRITER
|
| |
NUMBER
OF COMMON SHARES |
| |||
Jefferies LLC
|
| | | | | | |
Evercore Group L.L.C.
|
| | | | | | |
RBC Capital Markets, LLC
|
| | |
|
|
| |
Total
|
| | |
|
|
| |
|
| | |
PER SHARE
|
| |
TOTAL
|
| ||||||
| | |
WITHOUT
OPTION TO PURCHASE ADDITIONAL SHARES |
| |
WITH
OPTION TO PURCHASE ADDITIONAL SHARES |
| |
WITHOUT
OPTION TO PURCHASE ADDITIONAL SHARES |
| |
WITH
OPTION TO PURCHASE ADDITIONAL SHARES |
|
Public offering
price |
| | US$ | | | US$ | | | US$ | | | US$ | |
Underwriting discounts and commissions paid by us | | | US$ | | | US$ | | | US$ | | | US$ | |
Proceeds to us, before expenses
|
| | US$ | | | US$ | | | US$ | | | US$ | |
|
(Signed) ROBERTO BELLINI
President and Chief Executive Officer |
| |
(Signed) RAMZI BENAMAR
Chief Financial Officer |
|
|
(Signed) DR FRANCESCO BELLINI
Director |
| |
(Signed) PIERRE LAROCHELLE
Director |
|
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 2 | | | |
| | | | | 4 | | | |
| | | | | 6 | | | |
| | | | | 7 | | | |
| | | | | 10 | | | |
| | | | | 10 | | | |
| | | | | 12 | | | |
| | | | | 19 | | | |
| | | | | 20 | | | |
| | | | | 21 | | | |
| | | | | 22 | | | |
| | | | | 23 | | | |
| | | | | 24 | | | |
| | | | | 28 | | | |
| | | | | 34 | | | |
| | | | | 35 | | | |
| | | | | 35 | | | |
| | | | | 35 | | | |
| | | | | 36 | | | |
| | | | | 58 | | | |
| | | | | 58 | | | |
| | | | | 58 | | | |
| | | | | 58 | | | |
| | | | | 60 | | |
Dose
|
| |
Placebo-adjusted
reduction in awake cough frequency |
| |
P-value
|
| ||||||
25mg BID
|
| | | | -11% | | | | | | p=0.14 | | |
50mg BID
|
| | | | -6% | | | | | | p=0.46 | | |
100mg BID
|
| | | | -8% | | | | | | p=0.41 | | |
200mg BID
|
| | | | -17% | | | | | | p=0.09 | | |
Dose
|
| |
Placebo-adjusted
reduction in awake cough frequency |
| |
P-value
|
| ||||||
25mg BID
|
| | | | -20% | | | | | | p=0.0010 | | |
50mg BID
|
| | | | -18% | | | | | | p=0.0186 | | |
100mg BID
|
| | | | -19% | | | | | | p=0.0320 | | |
200mg BID
|
| | | | -27% | | | | | | p=0.0026 | | |
Dose
|
| |
Placebo-adjusted
reduction in awake cough frequency |
| |
P-value
|
| ||||||
25mg BID
|
| | | | -28% | | | | | | p=0.0005 | | |
50mg BID
|
| | | | -28% | | | | | | p=0.0003 | | |
100mg BID
|
| | | | -30% | | | | | | p=0.0014 | | |
200mg BID
|
| | | | -32% | | | | | | p=0.0006 | | |
|
(Signed) Roberto Bellini
President and Chief Executive Officer |
| |
(Signed) ramzi benamar
Chief Financial Officer |
|
|
(Signed) Dr Francesco Bellini
Director |
| |
(Signed) Pierre Larochelle
Director |
|
1 Year BELLUS Health Chart |
1 Month BELLUS Health Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions